In short
This article discusses a clinical trial investigating the use of recombinant human plasma gelsolin (rhu-pGSN) as a potential treatment for moderate-to-severe Acute Respiratory Distress Syndrome (ARDS) caused by pneumonia or other infections. The study aims to assess the safety and effectiveness of this drug when used alongside standard care in patients with ARDS.
At a glance
- Study Type
- Phase 2, Randomized, Double-blind, Placebo-controlled
- Condition
- Moderate-to-severe Acute Respiratory Distress Syndrome (ARDS) due to pneumonia or other infections
- Intervention
- Recombinant Human Plasma Gelsolin (rhu-pGSN) plus standard of care
- Control
- Placebo plus standard of care
- Primary Outcome
- All-cause mortality at Day 28
- Key Secondary Outcomes
- Ventilator-free days, mortality at Day 60, time to discontinuation of respiratory support
- Eligibility
- Age ≥18 years, moderate-to-severe ARDS (P/F ratio ≤150), evidence of infection
- Treatment Duration
- 6 doses
- Follow-up Period
- Up to 60 days
What is Recombinant Human Plasma Gelsolin (rhu-pGSN)?
Recombinant Human Plasma Gelsolin (rhu-pGSN) is a new medication being studied for the treatment of Acute Respiratory Distress Syndrome (ARDS). It's also known by other names such as B2988 or simply "gelsolin". This drug is a protein that is made in a laboratory to mimic a naturally occurring protein in our blood called plasma gelsolin.
rhu-pGSN comes in the form of a powder that is mixed into a solution and given to patients through an intravenous (IV) infusion, which means it's delivered directly into the bloodstream through a vein.
What is Acute Respiratory Distress Syndrome (ARDS)?
Acute Respiratory Distress Syndrome (ARDS) is a serious lung condition that causes difficulty breathing. It can occur when an infection, such as pneumonia, triggers inflammation in the lungs. This inflammation can cause fluid to build up in the tiny air sacs (alveoli) in the lungs, making it hard for oxygen to get into the blood.
ARDS can be life-threatening and often requires patients to be put on a ventilator (a machine that helps with breathing) in an intensive care unit (ICU).
How rhu-pGSN Works for ARDS
While the exact way rhu-pGSN works is still being studied, researchers believe it may help reduce inflammation in the lungs and improve oxygen levels in the blood of patients with ARDS. By mimicking the natural gelsolin in our bodies, it might help to control the body's immune response and reduce the damage caused by excessive inflammation.
Current Clinical Trial for rhu-pGSN
A clinical trial is currently underway to test the effectiveness and safety of rhu-pGSN for treating moderate to severe ARDS caused by pneumonia or other infections. This is a Phase 2 trial, which means it's designed to gather more information about how well the drug works and what side effects it might have.
The main goal of this trial is to see if adding rhu-pGSN to standard care treatments can improve outcomes for patients with ARDS compared to standard care alone.
Who Can Participate in the Trial?
The trial is looking for adult patients (18 years or older) who have moderate to severe ARDS due to an infection. Some key eligibility criteria include:
- Having ARDS for 48 hours or less
- Needing help with breathing (either through a ventilator, non-invasive ventilation, or high-flow oxygen)
- Having clear signs of an infection that led to ARDS
However, some conditions may prevent participation, such as:
- Heart failure or other heart conditions contributing to breathing problems
- Certain types of infections (like fungal or parasitic infections)
- Pregnancy or breastfeeding
- Recent organ transplants or active cancer treatments
What Happens During the Trial?
If a patient is eligible and agrees to participate in the trial, they will be randomly assigned to receive either rhu-pGSN or a placebo (a substance with no active ingredients) in addition to their standard care treatment. Neither the patient nor their doctor will know which one they're receiving.
Participants will receive six doses of either rhu-pGSN or placebo through an IV infusion. Throughout the trial, doctors will closely monitor the patient's condition, including how well they're breathing and any potential side effects.
Potential Benefits and Risks
The potential benefits of rhu-pGSN for ARDS patients could include:
- Improved survival rates
- Faster recovery from ARDS
- Less time needing a ventilator or other breathing support
- Shorter stays in the ICU and hospital
However, as with any new medication, there may be risks or side effects that are not yet known. The trial is designed to carefully monitor for any adverse effects to ensure patient safety.
It's important to note that this medication is still in the testing phase, and more research is needed to fully understand its effectiveness and safety for treating ARDS.